Eli Lilly is dropping the development of three therapies that did not meet expectations, including an acquired gene therapy.

As the oral weight loss drug market has started to emerge, AstraZeneca has told shareholders that it will advance its ...

Clinical trials are facing new and evolving challenges as costs increase and approval timelines remain lengthy. Modernisation ...

TransCode Therapeutics, in partnership with Quantum Leap Healthcare Collaborative, has submitted an IND application amendment ...

SEQSTER has announced the expansion of its partnership with Praxis Precision Medicines to expedite clinical trials in CNS ...

The Medicines and Healthcare products Regulatory Agency (MHRA) is formalising its review process around in vitro diagnostics ...

Evommune’s potential Dupixent competitor has met its primary endpoint in a Phase IIa atopic dermatitis (AD) trial, achieving a 33% reduction in Eczema Area and Severity Index (EASI).

This comes as Upstream Bio's twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing severe asthma exacerbations.

Nektar will now take Treg therapy, rezpeg to a Phase III trial in atopic dermatitis (AD), which is set to begin in Q2 2026.

The impact of Covid-19 pandemic included various downstream effects on health endpoints worldwide, including the increase in substance abuse.

Eli Lilly will speak with regulators about the Phase III data. Image credit: luchschenF / Shutterstock.com Eli Lilly’s oral targeted cancer therapy, Retevmo, has shown benefit as an adjunctive therapy ...

Roche will now share data from the Phase III MAJESTY study in membranous nephropathy with regulators. Image credit: Peakstock via ShutterStock.com. Roche is heading to regulators after its blockbuster ...